Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor Goffin et al1 provide model-based estimates on the cost-effectiveness of lung cancer screening in Canada. However, their analyses warrant additional clarification.
The authors state that they use general mortality rates. However, mortality differs substantially across different smoking behaviors.2 Therefore, the authors do not appropriately estimate the life-years and quality-adjusted life-years (QALYs) gained by screening.
ten Haaf K, de Koning HJ. Clarifying Assumptions and Outcomes in Cost-effectiveness Analyses. JAMA Oncol. 2016;2(2):277–278. doi:10.1001/jamaoncol.2015.4457
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: